An interventional study of high-density electroencephalography (hdEEG) and Transcranial alternating current stimulation (tACS) in Mild Cognitive Impairment, Alzheimer Disease and Memory Loss, sponsored by Lucie Bréchet. Recruiting at 1 site in Switzerland. Open to participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-15.
Sponsored by Lucie Bréchet · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 61 studies in Cognitive Dysfunction with a site in Switzerland — 17 open to participants now, 21 under way, 3 of them phase 3. Cognitive Dysfunction · Switzerland.
Among the 61 studies in Cognitive Dysfunction with a site in Switzerland, this one is the 14th largest by planned enrollment of the 48 interventional ones that give a count, is one of 3 that started in 2022, is one of 38 with no phase, reaches primary completion later than 9 of the 20 other live ones, and was the 39th registered.
3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.
Browse Cognitive Dysfunction studies →17 of the 61 studies in Cognitive Dysfunction with a site in Switzerland are open now. Recruiting first, the newest first:
Boris Quednow · Sites in Switzerland
Ages 20–50
University of Zurich · Sites in Switzerland
Ages 18+
University of Bern · Sites in Switzerland
Ages 60–85
Mclean Hospital · Sites in Switzerland, United States
Ages 18–35
Société des Produits Nestlé (SPN) · Sites in Switzerland, France, Germany and 3 more countries
Ages 60+
A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →
Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
61 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 4 · Phase 3 7 · Phase 4 2
First in 2010; this study’s year is marked. 3 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 120 is above the median of 64 across 2,804 interventional studies indexed under Cognitive Dysfunction.
Median enrollment 56 across the 48 interventional studies, 96 across the 13 observational. Of the 33 that completed or were terminated, 4 (12%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 61 have an industry lead sponsor. The 10 most frequent:
Lucie Bréchet is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
Lucie Bréchet has 2 studies filed under Cognitive Dysfunction — fewer than ten, so there is no comparison to draw.
5 of the studies in Cognitive Dysfunction with a site in Switzerland that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06191965Phase 3Mclean HospitalMitoQ for Early-phase Schizophrenia-spectrum Disorder and Mitochondrial Dysfunction | 2027-01-31 |
| NCT06207942Region SkaneStepcare Extended Follow-up Substudy | 2027-01 |
| NCT05710549Lucie BréchetUnderstanding Brain Mechanisms Involved in Autobiographical Memory | 2027-05-01 |
| NCT07532460Boris QuednowThe Role of Potassium Channels in Working Memory Impairments of Chronic Cocaine Users | 2027-08 |
| NCT05708001Lucie BréchetImprovement of Memory in Mild Cognitive Impairment | 2027-09-01 |
Add all 5 to your calendar (.ics) → With an account.
Among the 61 studies in Cognitive Dysfunction with a site in Switzerland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The overall objective of this project is to characterize the spatiotemporal dynamics of brain oscillations underpinning autobiographical memory (ABM) and the modulation of the memory network using non-invasive brain stimulation.
Accumulating evidence suggests that activity in distributed networks supporting ABM is altered even decades before the expected onset of clinical symptoms in Alzheimer's disease (AD). Robust network alterations associated with age-related memory and cognitive decline have been linked to abnormal oscillatory brain rhythmic activity and functional dysconnectivity. However, the detailed neural mechanisms are still poorly understood. The investigators propose to precisely characterize the underlying neurophysiological mechanisms that lead to behavioral and cognitive disturbances in ABM of MCI patients. Specifically, hdEEG will be used to characterize the sources and spatiotemporal dynamics of the neuronal activity involved in the ABM network of 40 mild cognitive impairment (MCI) patients and compare it to 40 age-matched, older healthy participants and 40 healthy young participants. The investigators will then apply non-invasive brain stimulation in the form of transcranial alternating current stimulation (tACS) to gain novel insights into the causal role of brain oscillations in the ABM network of MCI patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Cognitively-Unimpaired Younger and Older Adults
Mild Cognitive Impairment (MCI) patients
Exclusion Criteria:
Cognitively-Unimpaired Younger and Older Adults
Mild Cognitive Impairment (MCI) patients
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
40 cognitively-unimpaired healthy young adults (age 18-35 years old), 40 cognitively-unimpaired healthy older adults (age 55+ years old), and 40 age-matched patients with mild cognitive impairment (MCI) (age 55+ years old) will be assessed using high-density electroencephalography (hdEEG) to characterize the spatiotemporal dynamics of brain oscillations during personalized, autobiographical memory (ABM) tasks.
Device: high-density electroencephalography (hdEEG)
40 MCI patients (age 55+ years old) will undergo 20min multi-channel protocols of transcranial alternating current stimulation; tACS (either gamma, beta, or ActiSham stimulation randomized across the three laboratory sessions) to modify cognitive functioning (MoCA score), and oscillatory brain activity during performing personalized, autobiographical memory (ABM) tasks and resting-state EEG.
Device: Transcranial alternating current stimulation (tACS)
EEG will be recorded with a 257-channel EEG system (Geodesic Sensor Net, MegStim). An EEG net is applied at once on the head with evenly spaced sensors that provide full scalp coverage, including the cheek, Ag/Ag-Cl electrodes that are interconnected by thin rubber bands and contain small sponges soaked with saline water that touches the participant's scalp surface directly. Net application takes about 10 min to derive impedances to \<30 kOhms. EEG is recorded with 1 kHz and band-pass filtered between 0.1-200 Hz. Vertex electrode Cz is used as an acquisition reference.
tACS will be delivered by a battery-driven current stimulator Starstim SS32 (Neuroelectrics) through surface Ag/AgCl electrodes placed into holes of a neoprene cap corresponding to the international 10/20 EEG system. Gel (Parker Lab, Inc.) will be applied to optimize signal conductivity and lower impedance.
Spatiotemporal dynamic changes measured with electroencephalography (hdEEG)
Changes in spatiotemporal dynamics in different frequency bands (theta, alpha, beta, gamma) will be assessed with hdEEG
Time frame: up to 30 minutes
Cognitive Assessment
The Montreal Cognitive Assessment (MOCA) will be administered to characterize the cognitive status
Time frame: baseline
Started Apr 2022 (actual). Primary completion is estimated for May 2027, 60 months after the start.
Of 1,453 non-industry interventional studies with no phase under Cognitive Dysfunction, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 51. This study's planned 60 months is above that.
Counting every sponsor, half of 1,522 studies reached it within 27 months; a quarter within 12 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Lucie Bréchet